

Name	Enfuvirtide (T-20)
Cat #	PP-1230
Size	1 g, 10 g, 100, g and bulk custom packages
CAS#	159519-65-0
Mol. Mass	4492.1
Formula	C ₂₀₂ H ₂₉₈ N ₅₀ O ₆₄
Sequence	Ac-Tyr-Thr-Ser-Leu-Ile-His-Ser-Leu-Ile-Glu-Glu-Ser-Gln-Asn-Gln-Gln-Glu-Lys-Asn-Gln-Gln-Gln-Leu-Leu-Glu-Leu-Asp-Lys-Trp-Ala-Ser-Leu-Trp-Asn-Trp-Phe-NH ₂ ; Ac-YTSLIHSLIEESQNQQEKNEQELLELDKWASLWNWF-NH ₂
Purity	>95%

Enfuvirtide is a 36 residue synthetic peptide that inhibits HIV-1 fusion with CD4 cells. N-terminal acetylated C-terminal amide. It is a peptide mimetic of an essential region within viral envelope glycoprotein gp41 that functions by blocking gp41 structural rearrangements at a transitional pre-fusion conformation.

Enfuvirtide (INN) is an HIV fusion inhibitor, the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It is marketed under the trade name Fuzeon (Roche).

Enfuvirtide therapy costs an estimated USD\$25,000 per year in the United States. Its cost and inconvenient dosing regimen are factors behind its use as a reserve, for "salvage" therapy in patients with multi-drug resistant HIV

